Zymeworks Inc.
ZW191
platinum resistant ovarian cancer (PROC)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ZW191 in platinum resistant ovarian cancer (PROC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Part 2 of our Phase 1 study evaluating both 6.4 mg/kg and 9.6 mg/kg dose regimens in PROC is fully-enrolled with 60 total patients and remains ongoing”